Exscientia–Morgan Stanley: investor conference, 202409 supply service Exscientia to present at Morgan Stanley Annual Global Healthcare Conference 2024

	Period	2024-09-04
	Region	Boston, MA
	Country	United States (USA)
	Predecessor	Exscientia–Morgan Stanley: investor conference, 202309 supply service Exscientia to present at Morgan Stanley Annual Global Healthcare Conference 2023
	Partner, 1st	Exscientia plc (Nasdaq: EXAI)
	Group	Recursion Pharmaceuticals (Group)
	Partner, 2nd	Morgan Stanley & Co. LLC
	Group	Morgan Stanley (Group)
	Product	Morgan Stanley Global Healthcare Conference 2023 New York
	Product 2	AI-based drug discovery / AI-based drug development
	Person	Hallett, David (Exscientia 202001–COO before Evotec + Merck & Co)
	Person 2	Sherman, Sara (Exscientia 202109 Investor Relations)

Exscientia plc. (8/28/24). "Press Release: Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference". Oxford.

Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST).

A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at investors.exscientia.ai . An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of human ingenuity, artificial intelligence (AI), automation and physical engineering, we pioneered the use of AI in drug discovery as the first company to progress AI-designed small molecules into a clinical setting. We have developed an internal pipeline focused on oncology, while our partnered pipeline extends to many other therapeutic areas. By leading this new approach to drug creation, we believe we can change the underlying economics of drug discovery and rapidly advance the best scientific ideas into medicines for patients.

For more information visit us on www.exscientia.com or follow us on LinkedIn @ex-scientia and X @exscientiaAI .

Investor Relations:
Sara Sherman / Chinedu Okeke
investors@exscientia.ai

Media:
David Keown
media@exscientia.ai